[go: up one dir, main page]

TNSN08408A1 - PYRIDINE [3,4-b] PYRAZINONES - Google Patents

PYRIDINE [3,4-b] PYRAZINONES

Info

Publication number
TNSN08408A1
TNSN08408A1 TNP2008000408A TNSN08408A TNSN08408A1 TN SN08408 A1 TNSN08408 A1 TN SN08408A1 TN P2008000408 A TNP2008000408 A TN P2008000408A TN SN08408 A TNSN08408 A TN SN08408A TN SN08408 A1 TNSN08408 A1 TN SN08408A1
Authority
TN
Tunisia
Prior art keywords
pyrazinones
pyridine
compounds
methods
synthesis
Prior art date
Application number
TNP2008000408A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN08408A1 publication Critical patent/TNSN08408A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

Il est décrit des composés et des sels pharmaceutiquement acceptables des composés, lesdits composes ayant la structure de formule I : dans laquelle R2, R6A R6B et R8 sont tels que définis dans la description. Des compositions pharmaceutiques, méthodes de traitement, procédés de synthèse et intermédiaires correspondants sont également décrits.
TNP2008000408A 2006-04-21 2008-10-17 PYRIDINE [3,4-b] PYRAZINONES TNSN08408A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (fr) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
TNSN08408A1 true TNSN08408A1 (fr) 2010-04-14

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000408A TNSN08408A1 (fr) 2006-04-21 2008-10-17 PYRIDINE [3,4-b] PYRAZINONES

Country Status (41)

Country Link
US (1) US7902195B2 (fr)
EP (1) EP2013208B1 (fr)
JP (1) JP4436892B2 (fr)
KR (1) KR101061328B1 (fr)
CN (1) CN101454320B (fr)
AP (1) AP2408A (fr)
AR (1) AR060525A1 (fr)
AT (1) ATE513831T1 (fr)
AU (1) AU2007242555B2 (fr)
BR (1) BRPI0710658A2 (fr)
CA (1) CA2649775C (fr)
CR (1) CR10327A (fr)
CU (1) CU23777B7 (fr)
CY (1) CY1111739T1 (fr)
DK (1) DK2013208T3 (fr)
DO (1) DOP2007000080A (fr)
EA (1) EA014919B1 (fr)
EC (1) ECSP088803A (fr)
ES (1) ES2366239T3 (fr)
GT (1) GT200700035A (fr)
HR (1) HRP20110539T1 (fr)
IL (1) IL194591A (fr)
MA (1) MA30352B1 (fr)
ME (1) MEP23808A (fr)
MX (1) MX2008012456A (fr)
MY (1) MY148583A (fr)
NL (1) NL2000583C2 (fr)
NO (1) NO20084129L (fr)
NZ (1) NZ571540A (fr)
PA (1) PA8724201A1 (fr)
PE (1) PE20080192A1 (fr)
PL (1) PL2013208T3 (fr)
RS (2) RS20080484A (fr)
SI (1) SI2013208T1 (fr)
SV (1) SV2008003074A (fr)
TN (1) TNSN08408A1 (fr)
TW (1) TWI337609B (fr)
UA (1) UA92637C2 (fr)
UY (1) UY30291A1 (fr)
WO (1) WO2007122466A1 (fr)
ZA (1) ZA200808283B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2013208T1 (sl) 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CN101951909B (zh) 2008-03-05 2013-05-15 默克专利有限公司 作为胰岛素分泌刺激剂的吡啶并吡嗪酮类衍生物、获得它们的方法及其在治疗糖尿病中的用途
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ, エルエルシー ヘテロアリール化合物の合成方法および精製方法
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
EP2751116B1 (fr) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
CA2925743C (fr) 2013-10-04 2018-03-06 Pfizer Inc. Nouvelles pyridinones bicycliques utilisees comme modulateurs de gamma-secretase
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
SG11201607896YA (en) 2014-04-10 2016-10-28 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
EA033423B1 (ru) 2015-02-03 2019-10-31 Pfizer Циклопропанбензофуранилпиридопиразиндионы
MX389753B (es) 2015-06-17 2025-03-20 Pfizer Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CA3015166C (fr) 2016-02-23 2021-08-03 Pfizer Inc. Composes 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide
EP3478679B1 (fr) 2016-07-01 2021-04-21 Pfizer Inc. Dérivés de 5,7-dihydro-pyrrolo-pyridine pour le traitement de maladies neurologiques et neurodégénératives
ES2937236T3 (es) 2017-06-22 2023-03-27 Pfizer Derivados de dihidro-pirrolo-piridina
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
AR115015A1 (es) 2018-03-23 2020-11-18 Pfizer Derivados de azaespiro piperazina
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies
WO2025160132A1 (fr) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Agonistes inverses de gpr6

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
AU656154B2 (en) * 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
TW274550B (fr) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
CN1503797A (zh) * 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
WO2002076954A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005040337A2 (fr) * 2003-05-20 2005-05-06 The Regents Of The University Of California Procedes permettant de lier des agents a des plaques $g(b)-amyloides
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1833803A4 (fr) * 2005-01-03 2009-08-05 Myriad Genetics Inc Composes pharmaceutiques constituant des activateurs de caspases et des inducteurs d'apoptose et utilisation de ces composes
CA2608672A1 (fr) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones
KR20080052611A (ko) * 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
WO2007112347A1 (fr) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
SI2013208T1 (sl) 2006-04-21 2011-09-30 Pfizer Prod Inc Piridin(3,4-b)pirazinoni

Also Published As

Publication number Publication date
US7902195B2 (en) 2011-03-08
DK2013208T3 (da) 2011-08-15
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
RS20080484A (sr) 2009-07-15
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
SV2008003074A (es) 2010-01-12
CY1111739T1 (el) 2015-10-07
EP2013208A1 (fr) 2009-01-14
KR101061328B1 (ko) 2011-08-31
UY30291A1 (es) 2007-11-30
JP2009534368A (ja) 2009-09-24
AP2008004640A0 (en) 2008-10-31
BRPI0710658A2 (pt) 2011-08-16
TWI337609B (en) 2011-02-21
CU23777B7 (es) 2012-02-15
HRP20110539T1 (hr) 2011-08-31
EA200801998A1 (ru) 2009-04-28
WO2007122466A1 (fr) 2007-11-01
KR20080110930A (ko) 2008-12-19
CN101454320A (zh) 2009-06-10
AR060525A1 (es) 2008-06-25
TW200808794A (en) 2008-02-16
CU20080194A7 (es) 2011-03-21
EA014919B1 (ru) 2011-04-29
CR10327A (es) 2008-10-21
US20070249615A1 (en) 2007-10-25
NO20084129L (no) 2008-10-29
CA2649775A1 (fr) 2007-11-01
GT200700035A (es) 2008-02-05
DOP2007000080A (es) 2007-11-15
HK1133875A1 (en) 2010-04-09
MA30352B1 (fr) 2009-04-01
MY148583A (en) 2013-04-30
ZA200808283B (en) 2009-11-25
NL2000583A1 (nl) 2007-10-23
AU2007242555B2 (en) 2010-12-16
ECSP088803A (es) 2008-11-27
ATE513831T1 (de) 2011-07-15
CA2649775C (fr) 2011-05-31
ES2366239T3 (es) 2011-10-18
RS51885B (sr) 2012-02-29
PA8724201A1 (es) 2009-08-26
JP4436892B2 (ja) 2010-03-24
AU2007242555A1 (en) 2007-11-01
SI2013208T1 (sl) 2011-09-30
NZ571540A (en) 2010-10-29
EP2013208B1 (fr) 2011-06-22
MX2008012456A (es) 2008-10-10
PL2013208T3 (pl) 2011-10-31
IL194591A (en) 2012-07-31
PE20080192A1 (es) 2008-03-01
MEP23808A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
TNSN08408A1 (fr) PYRIDINE [3,4-b] PYRAZINONES
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
NL300929I2 (nl) Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2007135527A3 (fr) Composés de benzimidazolyle
SE0401971D0 (sv) Piperidne derivatives
MA31754B1 (fr) Cis-imidazolines chirales
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY30500A1 (es) Compuestos de azabencimidazolilo
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
EA017278B9 (ru) Соединения азаиндазола и способы применения
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
IN2012DN03182A (fr)
UA99787C2 (en) Lactams as beta secretase inhibitors
SE0401970D0 (sv) Novel compounds
WO2010033198A3 (fr) Analogues d'indole-3-carbinol et leur utilisation comme agents contre une infection
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
TW200738698A (en) Organic compounds
WO2004046122A3 (fr) Derives d'acides de benzoxazole, de benzothiazole, et de benzimidazole pharmaceutiquement actifs